Muscular Dystrophy Association

Rule Changes

Supported reauthorization

Congress finished work on the ACT for ALS Reauthorization Act on September 28, when the Senate gave final approval and sent the bill to the president. The vote came two days before the 2021 law was set to expire on September 30.

Updated Sep 29

New Capabilities

Welcomed the approval

The FDA approved Lisraya on August 27, 2026, clearing the first targeted therapy ever approved for dermatomyositis, a rare autoimmune disease that inflames skin and weakens muscles. The once-daily pill is now on sale in the US.

Updated Sep 16